Hongxia Wang

3.4k citations
42 papers · 1.8k indexed · h-index 18
Topics
MicroRNA in disease regulation (4 papers)Ubiquitin and proteasome pathways (3 papers)Caveolin-1 and cellular processes (3 papers)

In The Last Decade

Hongxia Wang

39 papers receiving 1.7k citations

Peers

Hongxia Wang
Comparison fields: 5 of 104
  • Molecular Biology 1.2k
  • Cancer Research 314
  • Epidemiology 256
  • Immunology 238
  • Oncology 221
Replace Rajesh Kumar Gandhirajan with:
Rajesh Kumar Gandhirajan Germany
Jason Karch United States
Yan Ru Su United States
Yun Zhong China
Shibo Tang China
Young Chul Yang United States
Yi Zhong China
Guoquan Gao China
Yong Geng China
Tong Yang United States
Hongxia Wang relative to Rajesh Kumar Gandhirajan Germany Rajesh Kumar Gandhirajan's profile →
Citations per field
00.5×
Rajesh Kumar Gandhirajan · 1×
Citations per year

Countries citing papers authored by Hongxia Wang

Since Specialization
Citations

This map shows the geographic impact of Hongxia Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hongxia Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hongxia Wang more than expected).

Fields of papers citing papers by Hongxia Wang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hongxia Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hongxia Wang. The network helps show where Hongxia Wang may publish in the future.

Co-authorship network of co-authors of Hongxia Wang

This figure shows the co-authorship network connecting the top 25 collaborators of Hongxia Wang. A scholar is included among the top collaborators of Hongxia Wang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hongxia Wang. Hongxia Wang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 0
2 0
3 9
4 1
5 0
6 28
7 4
8 5
9 54
10 31
11 4
12 46
13 67
14 3
15 139
16 20
17
Synergistic Effect of Multi-Ways Chinese Medication on Routine Therapy for Hepatitis B Virus Related Acute-On-Chronic Liver Failure
3
18 307
19 52
20 33

About Hongxia Wang

Hongxia Wang is a scholar working on Cancer Research, Cell Biology and Oncology, having authored 42 papers that have together received 1.8k indexed citations. Recurring topics across this work include MicroRNA in disease regulation (4 papers), Ubiquitin and proteasome pathways (3 papers) and Caveolin-1 and cellular processes (3 papers). The work is most often cited by research in Cancer Research (314 citations), Molecular Biology (1.2k citations) and Immunology (238 citations). Hongxia Wang has collaborated with scholars based in China, United States and Germany. Frequent co-authors include Jun Zhou, Min Liu, Olivier Gires, Peter Ping Lin, Bin Wang, Cheng Cao, Dengwen Li, Weili Tian, Yushan Zhu and Lei Du. Their work appears in journals such as Journal of Biological Chemistry, Molecular Cell and Nature Cell Biology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026